These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Brain Metastases and Place of Antiangiogenic Therapies in Alveolar Soft Part Sarcoma: A Retrospective Analysis of the French Sarcoma Group. Malouf GG; Beinse G; Adam J; Mir O; Chamseddine AN; Terrier P; Honore C; Spano JP; Italiano A; Kurtz JE; Coindre JM; Blay JY; Le Cesne A Oncologist; 2019 Jul; 24(7):980-988. PubMed ID: 30626710 [TBL] [Abstract][Full Text] [Related]
6. Diagnosis, Prognosis, and Treatment of Alveolar Soft-Part Sarcoma: A Review. Paoluzzi L; Maki RG JAMA Oncol; 2019 Feb; 5(2):254-260. PubMed ID: 30347044 [TBL] [Abstract][Full Text] [Related]
7. A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma. Kim M; Kim TM; Keam B; Kim YJ; Paeng JC; Moon KC; Kim DW; Heo DS Oncologist; 2019 Jan; 24(1):20-e29. PubMed ID: 30254189 [TBL] [Abstract][Full Text] [Related]
9. Cediranib for metastatic alveolar soft part sarcoma. Kummar S; Allen D; Monks A; Polley EC; Hose CD; Ivy SP; Turkbey IB; Lawrence S; Kinders RJ; Choyke P; Simon R; Steinberg SM; Doroshow JH; Helman L J Clin Oncol; 2013 Jun; 31(18):2296-302. PubMed ID: 23630200 [TBL] [Abstract][Full Text] [Related]
10. Cabozantinib and dastinib exert anti-tumor activity in alveolar soft part sarcoma. Mukaihara K; Tanabe Y; Kubota D; Akaike K; Hayashi T; Mogushi K; Hosoya M; Sato S; Kobayashi E; Okubo T; Kim Y; Kohsaka S; Saito T; Kaneko K; Suehara Y PLoS One; 2017; 12(9):e0185321. PubMed ID: 28945796 [TBL] [Abstract][Full Text] [Related]
11. iCREATE: imaging features of primary and metastatic alveolar soft part sarcoma from the EORTC CREATE study. Mcaddy NC; Saffar H; Litière S; Jespers P; Schöffski P; Messiou C Cancer Imaging; 2020 Oct; 20(1):79. PubMed ID: 33121537 [TBL] [Abstract][Full Text] [Related]
12. Angiogenesis-promoting gene patterns in alveolar soft part sarcoma. Lazar AJ; Das P; Tuvin D; Korchin B; Zhu Q; Jin Z; Warneke CL; Zhang PS; Hernandez V; Lopez-Terrada D; Pisters PW; Pollock RE; Lev D Clin Cancer Res; 2007 Dec; 13(24):7314-21. PubMed ID: 18094412 [TBL] [Abstract][Full Text] [Related]
13. Correlation of Immunological and Molecular Profiles with Response to Crizotinib in Alveolar Soft Part Sarcoma: An Exploratory Study Related to the EORTC 90101 "CREATE" Trial. Lee CJ; Modave E; Boeckx B; Kasper B; Aamdal S; Leahy MG; Rutkowski P; Bauer S; Debiec-Rychter M; Sciot R; Lambrechts D; Wozniak A; Schöffski P Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628499 [TBL] [Abstract][Full Text] [Related]
14. Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies. Groisberg R; Roszik J; Conley AP; Lazar AJ; Portal DE; Hong DS; Naing A; Herzog CE; Somaiah N; Zarzour MA; Patel S; Brown RE; Subbiah V Mol Cancer Ther; 2020 May; 19(5):1165-1172. PubMed ID: 32127467 [TBL] [Abstract][Full Text] [Related]
15. Novel therapeutic options for alveolar soft part sarcoma: antiangiogenic therapy, immunotherapy and beyond. Brahmi M; Vanacker H; Dufresne A Curr Opin Oncol; 2020 Jul; 32(4):295-300. PubMed ID: 32541316 [TBL] [Abstract][Full Text] [Related]
16. Modeling Alveolar Soft Part Sarcoma Unveils Novel Mechanisms of Metastasis. Tanaka M; Homme M; Yamazaki Y; Shimizu R; Takazawa Y; Nakamura T Cancer Res; 2017 Feb; 77(4):897-907. PubMed ID: 27979841 [TBL] [Abstract][Full Text] [Related]
17. Advanced alveolar soft part sarcoma responds to apatinib. Zhou Y; Tang F; Wang Y; Min L; Luo Y; Zhang W; Shi R; Duan H; Tu C Oncotarget; 2017 Jul; 8(30):50314-50322. PubMed ID: 28679123 [TBL] [Abstract][Full Text] [Related]
18. Stereotactic radiosurgery as a primary treatment for metastatic skull base alveolar soft part sarcoma: a case report. Shinya Y; Hasegawa H; Kawashima M; Shin M; Takahashi W; Kobayashi H; Saito N Acta Neurochir (Wien); 2021 Feb; 163(2):351-355. PubMed ID: 32686069 [TBL] [Abstract][Full Text] [Related]
19. A retrospective analysis of 14 consecutive Chinese patients with unresectable or metastatic alveolar soft part sarcoma treated with sunitinib. Li T; Wang L; Wang H; Zhang S; Atikan Kawuli ; Zhang X; Luo Z; Wang C Invest New Drugs; 2016 Dec; 34(6):701-706. PubMed ID: 27604635 [TBL] [Abstract][Full Text] [Related]
20. Mammalian target of rapamycin pathway activity in alveolar soft part sarcoma. Reis H; Hager T; Wohlschlaeger J; Bauer S; Katenkamp K; Katenkamp D; Baba HA Hum Pathol; 2013 Oct; 44(10):2266-74. PubMed ID: 23871289 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]